Role of Visfatin Chemerin with Type Two Diabetes Mellitus
DOI:
https://doi.org/10.36320/ajb/v11.i1.8031Keywords:
T2DM, Visfatin, Chemerin, GlucoseAbstract
A cross-sectional study was carried out in Kirkuk city from December 2016 to March 2017. The number of diabetic patients understudy were 180 whose ages were between 21-81 years old. These patients admitted to Kirkuk General Hospital and primary health care centers of Kirkuk first health care sector. The control group who were matched to the diabetic patients studied, included 90 healthy blood donors. Blood was collected for assessment of HbA1c test, blood glucose level, visfatin and chemerin levels. The study showed that the highest mean level of visfatin was found in diabetic patients comparing with healthy control ( 6.22±2.17 v.s. 3.54±1.91 ng/ml). The study showed that the highest mean level of chemerin was found in diabetic patients comparing with healthy control (146.13±12.67 v.s. 92.17±8.01 ng/ml). The study showed that the highest mean level of visfatin was found in diabetic patients who have elevated level of glucose and HbA1c (5.75±3.81 and 5.91±3.67 ng/ml) respectively, as compared with patients with normal level of glucose and HbA1c (4.61±2.99 and 3.95±2.12 ng/ml) respectively (P: ≤0.05). The study showed that the highest mean level of visfatin was found in diabetic patients who have elevated level of glucose and HbA1c (148.9±25.7 and 158.6±23.5 ng/ml) respectively, as compared with patients with normal level of glucose and HbA1c (111.5±14.6 and 105.1±15.7 ng/ml) respectively (P: ≤0.05), Table 5 and 6.
Downloads
References
Holt T, Kumar S. ABC of Diabetes. John Wiley & Sons; 2015 Jul 15.
Evelina L, Malic A, Niguleanu A, Maximovici V. Impact of diabetes mellitus on MDR-TB outcome.
Overbeek K, Krak N, Pieters I, Smits M, Bent R, Van Raalte D, Bruno M, Cahen D. Prevalence of cystic lesions and other morphological pancreatic abnormalities in type 2 diabetes mellitus patients. Pancreatology. 2018 Jun 30;18(4):S47.
Shier D, Butler J, Lewis R. Hole's essentials of human anatomy & physiology. New York: McGraw-Hill Education; 2015.
Simonson DC, Ding SA, Halperin F, Wewalka M, Foster K, Goebel-Fabbri AE, Hamdy O, Vernon A, Goldfine AB. Clinical and Patient-Centered Outcomes in Obese T2D Three Years after Randomization to Roux-en-Y Gastric Bypass vs. Intensive Diabetes and Medical Weight Management. InDIABETES 2016 Jun 1 (Vol. 65, pp. A69-A69). 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC.
Alkaf B, Lehne B, Kooner JS, Lessan N, Chambers JC, Barakat MT. Contribution of Adiposity to the Increased Risk of T2D in the UAE. InDIABETES 2016 Jun 1 (Vol. 65, pp. A404-A404). 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC.
Alhabbo DJ, Saeed ID, Khalaf YA. Frequency of Type 2 Diabetes in Young Age Groups in Northern Iraq. Iraqi Journal of Medical Sciences. 2018 Jan 1;16(1).
Alanzi T, Alanazi NR, Istepanian R, Philip N. Evaluation of the effectiveness of mobile diabetes management system with social networking and cognitive behavioural therapy (CBT) for T2D. mHealth. 2018;4.
Legakis I, Mantzouridis T, Bouboulis G, Chrousos GP. Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast. Archives of endocrinology and metabolism. 2016 Feb;60(1):76-8.
Cheon DY, Kang JG, Lee SJ, Ihm SH, Lee EJ, Choi MG, Yoo HJ, Kim CS. Serum chemerin levels are associated with visceral adiposity, independent of waist circumference, in newly diagnosed type 2 diabetic subjects. Yonsei medical journal. 2017 Mar 1;58(2):319-25.
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:R1–8.
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, et al. Elevated plasma level of visfatin/pre-B cell colonyenhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295–9.
Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007;85:399–404.
Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, Meysamie A. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes research and clinical practice. 2011 Feb 1;91(2):154-8.
Haddad NI, Nori E, Hamza SA. Correlations of Serum Chemerin and Visfatin with other Biochemical Parameters in Iraqi Individuals with Metabolic Syndrome and Type Two Diabetes Mellitus. Jordan Journal of Biological Sciences (JJBS). 2018:4369.
Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review. Diabetes/metabolism research and reviews. 2011 Sep;27(6):515-27.
Yanagawa T, Taniguchi A, Fukushima M, Nakai Y, Nagasaka S, Ohgushi M, Matsumoto K, Kuroe A, Ohya M, Seino Y. Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Diabetes research and clinical practice. 2007 Jan 1;75(1):2-6.
Katsareli EA, Dedoussis GV. Biomarkers in the field of obesity and its related comorbidities. Expert opinion on therapeutic targets. 2011.
Alghasham AA, Barakat YA. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi medical journal. 2008;29(2):185-92.
Berezin AE, Samura TA, Kremzer AA, Berezina TA, Martovitskaya YV, Gromenko EA. An association of serum vistafin level and number of circulating endothelial progenitor cells in type 2 diabetes mellitus patients. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2016 Oct 1;10(4):205-12.
Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism. 2007 Apr 1;56(4):565-70.
El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 2011 Jan 1;60(1):63-70.
Alfadda AA, Sallam RM, Chishti MA, Moustafa AS, Fatma S, Alomaim WS, Al-Naami MY, Bassas AF, Chrousos GP, Jo H. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism. Molecules and cells. 2012 Jun 1;33(6):591-6.
Du J, Li R, Xu L, Ma R, Liu J, Cheng J, Zhang Z, Sun H. Increased serum chemerin levels in diabetic retinopathy of type 2 diabetic patients. Current eye research. 2016 Jan 2;41(1):114-20.
Salama FE, Anass QA, Abdelrahman AA, Saeed EB. Chemerin: A biomarker for cardiovascular disease in diabetic chronic kidney disease patients. Saudi Journal of Kidney Diseases and Transplantation. 2016 Sep 1;27(5):977.
Skuja I, Stukena I, Lejnieks A. Chemerin Relationship with Glucose and Lipid Metabolism in Clinically Asymptomatic Patients. Fam Med Med Sci Res. 2015;5(193):2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Maad Mohammed Sulaiman, Khalid Nafi Salih, Muhannad Abdullah Alazzawy
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
